share_log

Morgan Stanley Maintains Overweight on Maravai LifeSciences, Lowers Price Target to $11

Morgan Stanley Maintains Overweight on Maravai LifeSciences, Lowers Price Target to $11

摩根士丹利维持对Maravai LifeSciences的增持,将目标股价下调至11美元
Benzinga ·  2023/11/09 09:26

Morgan Stanley analyst Tejas Savant maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and lowers the price target from $12 to $11.

摩根士丹利分析师Tejas Savant维持Maravai LifeSciences(纳斯达克股票代码:MRVI)增持 “增持”,并将目标股价从12美元下调至11美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发